Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation

IntroductionRivaroxaban is one of the most commonly used non-vitamin K antagonists for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual exposures exist for Asian and non-Asian populations, and dose selection is different for Japanese and non-Japanese s...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2022-06, Vol.12 (6), p.e058378
Main Authors: Liu, Xiao-Qin, Zhang, Yu-Fei, Ding, Hong-Yan, Yan, Ming-Ming, Zhong, Ming-Kang, Ma, Chun-Lai
Format: Article
Language:English
Subjects:
Anticoagulants
Anticoagulants - therapeutic use
anticoagulation
Atrial Fibrillation - drug therapy
Cardiac arrhythmia
clinical pharmacology
Clinical trials
East Asian People
Factor Xa Inhibitors - therapeutic use
Humans
Inpatients
Medical research
Pharmacodynamics
Pharmacokinetics
Pharmacology and Therapeutics
Prospective Studies
Rivaroxaban - adverse effects
Stroke
Stroke - epidemiology
stroke medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionRivaroxaban is one of the most commonly used non-vitamin K antagonists for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual exposures exist for Asian and non-Asian populations, and dose selection is different for Japanese and non-Japanese subjects. Few studies have investigated the pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in Chinese patients and provided a solid reference for dose selection and individualised therapy.Methods and analysisThis is a single-centre prospective study. Rivaroxaban-treated Chinese NVAF patients will be recruited according to predetermined inclusion criteria. Blood samples will be collected from both outpatients and inpatients with different sampling strategies at steady state. Rivaroxaban plasma concentration, factor Xa activity, prothrombin time and single-nucleotide polymorphisms of candidate genes will be evaluated. Follow-up will be conducted following 3 and 6 months after enrolment to collect information about the safety and efficacy outcomes. A nonlinear mixed-effects modelling strategy will be used to develop a population PK-PD model of rivaroxaban.Ethics and disseminationThe study has been approved by the Ethics Committee of Huashan Hospital, Fudan University (KY2020-016). The study findings will be submitted to peer-reviewed journals and shared with public health authorities.Trial registration numberChiCTR2100046685.
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2021-058378